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Two families of G protein-coupled receptors of the neurotransmitter dopamine, i.e., dopamine 1-like family (D1-like
receptor) and dopamine 2-like family (D2-like receptor), show dopaminergic activity in nerve cells. The D2-like
receptor family, composed of D2, D3, and D4 receptors, downregulates the intracellular cAMP signaling pathway,
and dopamine receptor agonists reduce the cAMP level in neurons. We previously demonstrated that the cAMP
level in epidermal keratinocytes is related to epidermal barrier homeostasis. Since keratinocytes are known to carry
various neurotransmitter receptors, we hypothesized that D2-like receptors on keratinocytes might be related to
skin barrier homeostasis. In this study, we examined the effect of topical application of receptor agonists and
antagonists on skin barrier recovery after barrier disruption. Application of D2-like receptor agonists accelerated
barrier recovery, whereas D2-like receptor antagonists delayed it. D2-like receptor agonists also reduced the ep-
idermal hyperplasia induced by barrier disruption under low environmental humidity. Immunohistochemical study
and RT-PCR analysis revealed the expression of the D2 receptor in the basal epidermis and the D4 receptor in the
uppermost layer of the epidermis. These results suggest that dopaminergic receptors are involved in epidermal
barrier homeostasis.
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One of the most important roles of the skin is to form a
water-impermeable barrier in the uppermost epidermis,
called the stratum corneum (SC). When the barrier is
disrupted, a series of homeostatic processes is accelerat-
ed and the original barrier function is restored (Elias and
Feingold, 2001). If the disruption is repeated or occurs un-
der a dry condition, however, marked epidermal hyperplasia
and inflammation are induced, even if the degree of barrier
disruption is relatively small (Denda et al, 1996, 1998a).
Thus, skin barrier homeostasis is important in relation to
skin pathology.
We have recently demonstrated that several ionotropic
receptors, which were originally found in the nervous sys-
tem, play an important role in homeostasis of the skin per-
meability barrier (Denda et al, 2002a, b; Fuziwara et al,
2003). For example, topical application of NMDA receptor
agonists after barrier disruption delayed the barrier repair,
whereas NMDA receptor antagonists accelerated it (Fuzi-
wara et al, 2003). GABA (A) receptor and purinergic receptor
(P2X) also play roles in skin permeability barrier home-
ostasis (Denda et al, 2002a, b). These results suggest that
various neurotransmitters are involved in epidermal barrier
homeostasis.
Not only ionotropic receptors, but also metabotropic re-
ceptors are involved in skin barrier homeostasis. Topical
application of an adrenergic b-2 receptor antagonist accel-
erated the barrier recovery. Activation of Gs protein-binding
protein, an adrenergic b-2 receptor, upregulates intracellular
cAMP (Denda et al, 2003a). We also demonstrated that the
level of cAMP in the epidermis is associated with skin bar-
rier homeostasis (Denda et al, 2004). Increase of cAMP in
the epidermis delayed barrier repair, whereas a decrease of
cAMP accelerated barrier recovery. Thus, neurotransmitters
that activate Gs or Go/Gi proteins might affect skin barrier
homeostasis.
Dopamine is a neurotransmitter which plays an important
role in the central nervous system. There are five subtypes
of dopamine receptor, and they have been categorized into
two families, i.e., D1-like receptors (D1 and D5) and D2-like
receptors (D2, D3, and D4) (Watson and Arkinstall, 1994).
The D2-like receptor agonists activate Go/Gi proteins and
inhibit neuronal activity by downregulation of the intracel-
lular cAMP signaling pathway (Watson and Arkinstall, 1994).
Application of dopamine has been reported to decrease
mitosis of keratinocytes (Harper and Flaxman, 1975). Thus,
we hypothesized that the D2-like receptor exists on epider-
mal keratinocytes and plays an important role in cutaneous
barrier homeostasis through the regulation of intracellular
cAMP in epidermal keratinocytes. In this study, we first ex-
amined the effects of topical application of D2-like receptor
agonists and antagonists on skin barrier homeostasis and
epidermal proliferation. We also examined the localization of
D2-like receptors in the epidermis of hairless mouse. Then,
we investigated the effects of D2-like receptor agonists and
antagonists on the level of cAMP in the epidermis, and on
keratinocyte proliferation.
Abbreviations: SC, stratum corneum; SG, stratum granulosum;
TEWL, transepidermal water loss
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Results
We first evaluated the effects of topical application of
agonists and antagonists of the D2-like receptor on the
barrier recovery rate (Fig 1A, B). Each reagent was applied
immediately after tape stripping. Topical application of
D2-like receptor agonists, quinpirole, bromocriptine, and
PD168077, accelerated barrier recovery (Fig 1A). On the
other hand, application of D2-like receptor antagonists, L-
741626, L-741742, and remoxidride, delayed barrier repair
(Fig 1B). These results suggest that activation of the D2-like
receptors accelerated barrier recovery, whereas application
of antagonists delayed the recovery.
We next examined the effects of topical application of an
agonist and antagonist of D2-like receptors on epidermal
proliferation induced by barrier disruption under low envi-
ronmental humidity (Denda et al, 1998a). The results are
shown in Fig 2A and representative microscopic images are
shown in Fig 2B–E (B, untreated control; C, acetone-treated
skin; D, bromocriptin-treated skin; E, L-741626-treated
skin, scale bars¼10 mm). Topical application of the D2-like
receptor agonist bromocriptine reduced the epidermal
hyperproliferation induced by barrier disruption under low
environmental humidity, whereas L-741,626, a D2-like re-
ceptor antagonist, enhanced epidermal hyperplasia. These
results suggest that D2-like receptors might be involved in
the epidermal proliferative responses.
The results of immunohistochemical study and RT-PCR
analysis are shown in Fig 3 (A, D2; B, D4; C, control).
Immunoreactivity with dopamine D2 receptor antibody was
observed in the basal layer of the epidermis, whereas
immunoreactivity to dopamine D4 receptor antibody was
observed in the uppermost part of the epidermis. Immuno-
reactivity against D3 receptor antibody was not observed in
the hairless mouse epidermis (data not shown). RT-PCR
analysis for mouse D2 receptor and D4 receptor using total
RNA from mouse epidermis also showed positive bands of
the expected sizes (Fig 3D).
We recently demonstrated that the cAMP level in the epi-
dermis is associated with barrier homeostasis (Denda et al,
2004). In that study, barrier disruption increased the cAMP
level in the epidermis and application of a cAMP antagonist
accelerated barrier recovery. In this study, barrier disruption
increased the intracellular cAMP level and the increase was
reduced by bromocriptine and quinpirole, both D2-like re-
ceptor agonists, and also by PD168077, a D4 receptor ago-
nist (Fig 4). On the other hand, application of L-741626, a D2
receptor antagonist, and L-741742, a D4 receptor antagonist,
significantly enhanced the elevation of cAMP by tape strip-
ping. These results support our previous findings (Denda et al,
2004), i.e., a reduction of cAMP in the epidermis accelerated
barrier recovery and an increase of cAMP delayed it.
As shown in Fig 2, application of D2-like receptor an-
tagonists delayed barrier repair. This suggests the existence
of endogenous dopamine in the epidermis. Ramchand et al
(1995) suggested the existence of a dopamine-synthesizing
Figure 1
Topical application of dopamine D2-like receptor agonists and
antagonists affected the skin barrier recovery rate. (A) Topical
application of agonists of D2-like receptors, quinpirole (1 mM), bromoc-
riptine (100 nM), and PD168077 (100 nM), accelerated skin barrier re-
covery measured at 1, 3, and 6 h after tape stripping. (B) Topical
application of antagonists of D2-like receptors, L-741626 (100 nM), L-
741742 (100 nM), and remoxipride (1 mM), delayed skin barrier recovery
at 1, 3, and 6 h after tape stripping. Concentration of all reagents was 1
mM. Four mice were used for each measurement. The ordinate shows
percent recovery of the barrier with respect to the original level.
po0.05; po0.005; po0.0005; bar, SD.
Figure 2
Localization of dopamine D2 and D4
receptor in the epidermis. Topical ap-
plication of 100 nM bromocriptine, a
D2-like receptor agonist, reduced epi-
dermal hyperproliferation induced by
barrier disruption under low environ-
mental humidity, whereas application
of 100 nM L-741626, a D2-like receptor
antagonist, enhanced epidermal hyper-
proliferation. (A) Quantitative results.
p¼ 0.0156 for difference between control
and bromocriptine. Thus, application of
bromocriptine significantly, though not
completely, blocked the epidermal hype-
rplasia following tape stripping. (B) Un-
treated control, (C) acetone-treated skin
in a dry condition, (D) bromocriptine-
treated skin after acetone treatment, (E)
L-741626-treated skin after acetone treat-
ment. Scale bars¼10 mm.
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enzyme in keratinocytes. We detected secretion of dopa-
mine into the medium of keratinocyte culture (Fig 5). The
baseline level of dopamine in the initial medium was 2.22
nM, whereas the medium after the culture of keratinocytes
contained 8.62 nM dopamine, i.e., at least 6.40 nM dopa-
mine had been synthesized by keratinocytes during the in-
cubation. The dopamine level in epidermis from four
hairless mice was 18.24 nmol per mg protein (SD¼0.74).
We next evaluated the effect of bromocriptine on the
delay of barrier repair induced by the application of fors-
Figure 3
Immunoreactivity to anti-D2 receptor an-
tibody is seen in the basal layer of the
epidermis (A), whereas immunoreactivity
to anti-D4 receptor antibody is seen in the
upper layer (B). (C) The results of staining
without the first antiserum as a control.
RT-PCR analysis for mouse D2 and D4
receptors using total RNA from mouse
epidermis also showed positive bands of
the expected sizes (D).
Figure 4
The level of cAMP in the epidermis was increased by barrier dis-
ruption in agreement with our previous findings (Denda et al, 2004).
The increase was partially blocked by bromocriptine, quinpirole (a D2-
like agonist), and PD168077 (a D4 agonist). On the other hand, the
increase was enhanced by L-741626 (a D2 antagonist) and L-741742
(a D4 antagonist). The error bars show SD.
Figure5
Detection of dopamine in the incubation medium of keratinocytes.
The small peak, appearing at the same retention time in the control,
might have originated from dopamine contaminating the medium. The
baseline level of dopamine in the initial medium was 2.22 nM, whereas
the medium after the incubation of keratinocytes contained 8.62 nM
dopamine, i.e., at least 6.40 nM dopamine was synthesized by kera-
tinocytes during the incubation. X axis shows the potential (mV) which
correlated to the amount of oxidated dopamine.
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kolin, which increases the intracellular cAMP level. As
shown in Fig 6, the delay of barrier repair induced by fors-
kolin was blocked by the pre-application of bromocriptine.
Finally, we examined the effect of bromocriptine (a D2-like
receptor agonist) and L-741626 (a D2 receptor antagonist)
on keratinocyte proliferation in culture. As shown in Fig 7A,
bromocriptine significantly reduced keratinocyte prolifera-
tion. This is consistent with the in vivo data in Fig 2. Appli-
cation of L-741626, however, did not have any significant
effect in this in vitro study. In the in vivo study (Fig 2), topical
application of L-741626 significantly enhanced epidermal
hyperplasia induced by barrier disruption. This in vivo effect
of L-741626 might be due to elongation of the delay in bar-
rier recovery, as shown in Fig 1. The results of Alamar Blue
assay are shown in Fig 7B. The levels of fluorescence in-
dicate the activity of mitochondria, which is considered to be
a measure of the viability of the cells (Reid et al, 2001). In this
study, the viability closely paralleled the cell number, indi-
cating that the reduction of keratinocyte proliferation by
bromocriptine was not due to cytotoxicity of the reagent.
Discussion
We previously demonstrated that several neurotransmitters
are involved in epidermal permeability barrier function. For
example, topical application of an NMDA agonist, nicotine,
and ATP delayed barrier recovery, whereas application of
GABA and glycine accelerated it (Denda et al, 2002a, b,
2003b; Fuziwara et al, 2003). These results suggest that the
ion flux through ionotropic receptors is associated with skin
barrier homeostasis (Denda et al, 2003b).
The D2-like receptor is not an ionotropic receptor, but a
Gi/o protein-coupled receptor, which induces a second
messenger in the cell. Recently, we demonstrated that ad-
renergic b2 receptor, which is also not an ionotropic recep-
tor, is involved in skin barrier homeostasis (Denda et al,
2003a). Topical application of a b2 receptor agonist delayed
barrier repair, whereas application of an adrenergic b2 re-
ceptor antagonist accelerated it. The adrenergic b2 recep-
tor is a Gs protein-coupled receptor, and its activation
increases the cAMP level. We demonstrated that barrier
disruption increased the cAMP level in the epidermis, and
topical application of an antagonist of cAMP after barrier
disruption accelerated barrier recovery, whereas application
of folskolin, which accelerates cAMP synthesis, delayed
barrier recovery. The dopaminergic D2-like receptor is a Gi/
o protein-coupled receptor, and activation of Gi/o reduces
intracellular cAMP. As shown in Fig 4, bromocriptine re-
duced the increase of cAMP caused by barrier disruption.
The level of intracellular cAMP might be a crucial factor in
epidermal barrier homeostasis.
Application of a D2-like receptor antagonist alone de-
layed barrier repair. This result suggested the existence of
an endogenous ligand of the receptor in the epidermis after
barrier disruption. Ramchand et al (1995) suggested that
epidermal keratinocytes can produce dopamine. Figure 5
also indicates that dopamine is secreted from keratin-
ocytes. We previously demonstrated that neurotransmitters,
such as ATP and glutamate, were released from the epi-
dermis immediately after skin barrier disruption (Denda et al,
2002a; Fuziwara et al, 2003). Dopamine might also be se-
creted in response to barrier disruption.
Grando (1997) demonstrated that two types of choliner-
gic receptors are localized differently in the epidermis. Mu-
scarinic acetylcholine receptors are localized in the basal
Figure 6
Forskolin (100 lM)-induced delay of barrier recovery was blocked
by pre-application of bromocriptine (1 mM). A–C showed percent
barrier recovery 1, 3, and 6 h after tape stripping and following the
topical application of the reagents.
Figure7
Effects of bromocriptine and L-741626 on proliferation and
cytotoxicity of cultured keratinocytes. (A) Application of 10 nM
bromocriptine significantly reduced keratinocyte proliferation, whereas
L-741626 did not affect proliferation in a human keratinocyte culture
system. (B) The results of Alamar Blue assay paralleled the keratinocyte
proliferation data, indicating that the reduction of keratinocyte prolif-
eration by bromocriptione was not due to cytotoxicity of the reagent.
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layer of the epidermis, whereas nicotinic acetylcholine re-
ceptors are localized in the upper layer. He suggested that
these receptors play different roles in the epidermis and
maintain a balance of proliferation and differentiation of the
epidermis (Grando, 1997). In this study, two types of dopa-
mine receptor protein showed different localization in the
epidermis. D4, which is localized in the uppermost part of
the epidermis, might be involved in barrier homeostasis,
whereas D2 might play a role in the proliferative response in
the basal layer of the epidermis. The roles of these proteins
remain to be fully clarified.
In this study, D2 receptor agonist and antagonist affected
the barrier homeostasis, even though D2 receptors were
observed in the basal layer of the epidermis. Here, it is im-
portant to recognize the cross reactivity between D2-re-
ceptor reagents and D4-receptor reagents. The term D2-like
receptor refers to D2, D3, and D4 receptors, whereas D1,
D5, and D5 receptors are categorized as D1-like receptor.
D2-receptor reagents often affect D4 receptor and D4-re-
ceptor reagents also often affect D2 receptor (Seeman and
Van Tol, 1994). The two receptors have similar effects on
intracellular cAMP levels, as we demonstrated in this study.
Thus, D2 receptor reagents might affect keratinocytes in the
uppermost epidermis via D4 receptors to influence barrier
repair, whereas D4 receptor reagents might affect keratin-
ocytes in the basal layer of the epidermis via D2 receptors.
Another possibility is the existence of unknown signaling
between the uppermost epidermis and the basal layer. For
example, when the intracellular cAMP level changes, the
electrical potential of the keratinocyte membrane is altered,
and this in turn affects the adjacent cells via voltage-gated
ion channels. Thus, stimulation of basal keratinocyes might
affect barrier homeostasis through signal transmission to
keratinocytes at the uppermost epidermis. Further study is
needed to examine this possibility.
Previous studies have demonstrated that acceleration of
barrier recovery also inhibits epidermal hyperplasia follow-
ing barrier disruption (Denda et al, 1997; Ashida et al, 2001).
In this study, acceleration of the barrier recovery by a D2-
like receptor agonist reduced epidermal hyperplasia under
low environmental humidity. These results suggest a new
strategy for preventing dermatoses, which are character-
ized by epidermal proliferation and barrier dysfunction.
In conclusion, topical application of D2-like receptor
agonists accelerated barrier recovery whereas the applica-
tion of D2-like receptor antagonists delayed it. Application
of a D2-like receptor agonist also blocked epidermal hype-
rplasia induced by barrier disruption in a dry environment.
Immunoreactivity to D2-receptor protein antibody and D4-
receptor antibody was observed in the epidermis. These
results suggest that dopaminergic receptors play an impor-
tant role in skin permeability barrier homeostasis.
Materials and Methods
All experiments were performed on 7–13-wk-old male hairless
mice (HR-1, Hoshino, Yashio, Saitama, Japan). All procedures for
measuring skin barrier function, disrupting the barrier and applying
samples were carried out under anesthesia. All experiments were
approved by the Animal Research Committee of the Shiseido Re-
search Center in accordance with the National Research Council
Guide (National Research Council, 1996). L-741626 (D2 antago-
nist), remoxpride (D2-like antagonist, Ki value (nM) D2–300,
D3–1699, D4–2800), bromocriptine (D2-like agonist, Ki value (nM)
D2–8, D3–5, D4–290), PD168077 (D4 agonist), quinpirole (D2-like
agonist), and L-741742 (D4 antagonist) (Seeman and Van Tol, 1994)
were purchased from Tocris Cookson (Avonmouth, UK).
Cutaneous barrier function Permeability barrier function was
evaluated by measurement of transepidermal water loss (TEWL)
with an electric moisture analyzer (Meeco, Warrington, Pennsyl-
vana), as described previously (Denda et al, 1998a). Four mice
were used for each treatment. For barrier recovery experiments,
the skin on both flanks was treated with repeated tape stripping
until the TEWL reached 7–10 mg per cm2 per h, as described
previously (Denda et al, 1998b). Immediately after barrier disrup-
tion, 100 mL of an aqueous solution containing the reagent or water
alone (control) was applied to the treated area. A different reagent
was applied on the other flank. The areas were covered with plastic
film for 15 min, then the plastic was removed. Two points on each
flank were measured and 4–8 mice were used to evaluate the ef-
fects of each treatment. We always disrupted the barrier between
7:00 AM and 8:00 AM and immediately carried out measurements
of barrier repair to avoid any influence of circadian rhythm on the
barrier repair (Denda and Tsuchiya, 2000). TEWL was then meas-
ured over the same sites at 1, 3, and 6 h after barrier disruption.
The barrier recovery results are expressed as percent recovery,
because of variations from day to day in the extent of barrier dis-
ruption. In each animal, the percent recovery was calculated by
means of the following formula: (TEWL immediately after barrier
disruptionTEWL at indicated time point)/(TEWL immediately after
barrier disruptionbaseline TEWL)  100%.
Epidermal hyperplasia induced by barrier disruption under low
environmental humidity Animals were kept separately in 7.2 L
cages in which the relative humidity was maintained at less than
10% with dry air as described previously (Denda et al, 1998a). Four
mice were used for each treatment. The temperature was the same
in all cases (221C–251C), and fresh air was circulated 100 times per
hour. Animals were kept out of the direct stream of air. During the
experiments, the animals’ behavior was not restricted. The level of
NH3 was always below 1 ppm. Animals were first kept in a dry
condition for 48 h and then the skin on both flanks was treated with
acetone-soaked cotton balls, as described previously (Denda et al,
1998a). The procedure was terminated when TEWL reached 2.5–
3.5 mg per cm2 per h. Immediately after the barrier disruption, 100
mL of L-741624 (100 nM), bromocriptine (100 nM), remoxpride (1
mM), PDI68077 (100 nM), quinpirole (1 mM), or L-741742 (100 nM)
was applied to the treated area of one flank. Water was applied on
the other flank. Then the animals were again kept in a dry condition
for 48 h. After the experiments, animals were euthanized with di-
ethylether inhalation and skin samples were taken from the treated
area. One hour prior to this, 20 mL per g body weight of 10 mM
bromodeoxyuridine (BrdU) solution was injected intraperitoneally.
Untreated control mice were also treated with BrdU at the same
time. After fixation with 4% paraformaldehyde, full thickness skin
samples were embedded in paraffin, sectioned (4 mm), and proc-
essed for hematoxylin and eosin staining. On each section, five
areas were selected at random; the thickness of the epidermis was
measured with an optical micrometer, and the mean value was
calculated. For the assessment of DNA synthesis, the sections
were immunostained with anti-BrdU antibodies. On each section,
five areas were selected at random from one section; the number
of immunostained cells per 1 mm of epidermis was counted and
the mean value was calculated. Measurements were carried out in
an observer-blinded fashion.
Immunohistochemistry Polyclonal antisera to D2, D3, and D4
receptors were purchased from Alpha Diagnostic International
(San Antonio, Texas). The antiserum was diluted 500:1 with block-
ing solution, i.e., 3% bovine albumin PBS solution containing 10%
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heat-inactivated goat serum and 0.4% Triton X-100. A fluorescent
secondary antibody was purchased from Molecular Probes (Eu-
gene, Oregon) (Alexa Fluor 594, anti-rabbit IgG conjugate). The
secondary antibody was also diluted 500:1 with the blocking so-
lution. A 5 mm frozen skin section was fixed with 201C methanol
for 10 min, soaked in PBS solution, and blocked with blocking
solution for 1 h at room temperature. The section was covered with
diluted antiserum solution and kept at 41C overnight. It was then
washed with PBS solution containing 0.05% Tween 20 for 15 min
three times and covered with the secondary fluorescent antibody
solution for 1 h at room temperature. Then the section was washed
with PBS solution containing 0.05% Tween 20 for 15 min three
times, and mounted with Vectashield (Vectashield with dapi, Vector
Laboratories, Burlingame, California). The section was observed
and photographs were taken within 6 h.
RT-PCR Epidermis of the skin tissue was removed by incubation
with 10 mM EDTA PBS solution at 371C for 30 min. Mouse total
RNA was obtained from epidermis using TRIzol reagent (Gibco,
BRL, Grand Island, New York). cDNA was produced from the RNA
by oligo dT priming and reverse transcription was done using Su-
perScript II (Life Technologies), according to the manufacturer’s
instructions. RT-PCR was carried out using a TaKaRa ExTaq Hot
Start Kit (Takara Shuzo, Shiga, Japan) with sense and antisense
oligonucleotide primers designed for mouse D2 receptor and D4
receptor, respectively (D2 NCBI accession number: NM 010077
and D4: NM 007878). The primer sequences were as follows: D2
sense: AACAGTGCCGTGAACCCCATCATCTATACC, antisense:
CCTTCTCTTCTACCACCTGATCCAACATAG, D4 sense: CTCTCC
CGCAACCTCCTGAGCCGTCTTCCC, antisense: CACACAGTCTT
GGAACTCCTTGACCTCTGC. The denaturing temperature and the
polymerase working temperature were 981C and 721C for 1 min,
respectively. Annealing was carried out at 601C for 1 min. This
program was carried out for 35 cycles.
Human keratinocyte cell culture Human neonatal keratinocytes
were purchased from BioWhittaker (Walkersville, Maryland). All in
vitro cell culture measurements were carried out using human
neonatal keratinocytes at the second to fourth passage.
Quantiﬁcation of dopamine in cultured human keratin-
ocytes Human neonatal keratinocytes were purchased from Bio-
Whittaker. Medium for the culture system was purchased from
Sanko Junyaku (Tokyo, Japan, KGM-2). All in vitro cell culture
measurements were carried out using human neonatal keratin-
ocytes at the fourth passage. We first seeded 3  104 cells. After a
48 h incubation, medium was taken for analysis. At that time, the
cells were 80%–90% confluent. Dopamine quantification was per-
formed by high-pressure liquid chromatography (HPLC) with elec-
tron capture detection (ECD). A NANOSPACE SI-1 semi-micro
HPLC system (Shiseido, Tokyo, Japan) was used for separation.
The column was a Capcell Pack C18 UG120 S5 (Shiseido) for
HPLC. A NANOSPACE SI-2/3005 (Shiseido) was employed for
ECD. The solvent consisted of water–acetonitrile (95:5, vol/vol)
containing 0.7 mM sodium octanesulfonate (WAKO, Osaka, Ja-
pan), 0.02 mM EDTA 2Na (WAKO), and 0.1 M potassium dihydro-
genphosphate (WAKO), adjusted to pH 3.0 with phosphoric acid
(WAKO). The solvent flow rate was 100 mL per min at 301C. A 2 mL
aliquot was injected into the column and ECD detection was car-
ried out under OX 650 mV (Ag per AgCl). The amount of dopamine
was determined using Catecholamines Standard Solution (WAKO).
Quantiﬁcation of dopamine in hairless mouse epidermis Skin
samples (2  2 cm2) were taken from four male hairless mice (8 wk
old) and fat was removed with a scalpel. The skin was incubated in
the same medium as used in the human culture experiments to
remove dopamine from blood or neurons. Then the epidermis was
removed by heating (601C for 1 min). The epidermis was homog-
enized with 1 mL 0.1% Triton-X/0.1 N HCl/10 mM ascorbic acid,
and centrifuged in a spin column to remove debris. An aliquot was
taken for protein assay and the dopamine quantification by the
same method that we used for dopamine assay of cultured human
keratinocytes.
cAMP evaluation Mice were euthanized by diethylether inhalation
and skin samples were immediately taken from both flanks. The
level of cAMP in skin is readily influenced by systemic factors
(Saitoh et al, 1980). Thus, we performed an in vitro study. Pieces of
skin from both flanks were placed, epidermis side upwards, in PBS
buffer in separate culture dishes kept at 371C, and one of them was
tape stripped four times; the other was not treated. Four tape
strippings usually reduced the TEWL to approximately 7–10 mg per
cm2 per h. After a 1-h incubation, the skin was put on a hot plate
(601C) for 30 s and the epidermis was separated. The epidermis
was homogenized in PBS and centrifuged to remove large parti-
cles. An aliquot was removed for assay of both cAMP and protein.
cAMP in samples containing 0.1 M HCl was quantified by immuno-
assay with a cAMP enzyme immunoassay (EIA) kit (Sigma, St
Louis, Missouri) according to the manufacturer’s instructions.
Evaluation of the effects of bromocriptine and L-741626 on
keratinocyte proliferation We used second-to-fourth-passage
keratinocytes in this study. There was no significant difference be-
tween the results obtained with second- and fourth-passage cells.
First, we seeded 3  104 keratinocytes per well in 12-well plates
with 2 mL of KG2 medium (Kurabo, Osaka, Japan) and incubated
them for 48 h. Then, the medium was changed and bromocriptine
(final concentration 10 nM) or L-741626 (final concentration 10 nM)
was applied. Incubation was continued for another 48 h; then the
cells were washed with PBS, and treated with 150 mL of 1% trypsin
and 1 mM EDTA. Finally, 150 mL of 1% trypsin inhibitor was added,
and the cells in a 10 mL aliquot of the 300 mL suspension were
counted. The number of cells per well was calculated.
Alamar blue assay To evaluate the cytotoxicity of bromocriptine
and L-741626, we carried out Alamar blue assay (Reid et al, 2001).
First, we seeded 3x104 keratinocytes per well in 12-well plates with
2 mL of KG2 medium (Kurabo) and incubated them for 48 h. Then,
the medium was changed and bromocriptine (final concentration
10 nM) or L-741626 (final concentration 10 nM) was applied. In-
cubation was continued for another 48 h, and then the cells were
washed with PBS. The cells were incubated in 1 mL of KG2 me-
dium containing 10% Alamar Blue (TREK Diagnostic Systems,
Cleveland, Ohio) for 1 h. Then the fluorescence of each medium
was evaluated with a Fluoroskan Ascent FL Plate Reader (Thermo
Labsystems, Helsinki, Finland). On the other hand, the cells were
washed with PBS, and treated with 150 mL of 1% trypsin and 1 mM
EDTA. Finally, 150 mL of 1% trypsin inhibitor was added and the
cells in a 10 mL aliquot of the 300 mL suspension were counted. The
number of cells per well was calculated.
Statistics The results are expressed as the mean  SD. The sta-
tistical significance of differences between two groups was deter-
mined by means of a two-tailed Student’s t test. In the case of
more than two groups, we first carried out ANOVA and then the
significance of differences between groups was determined by
means of Fisher’s protected least significant difference (PLSD) test.
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